{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Viklicky O"],"pubmed_abstract":["Background
There is high medical need for safe long-term immunosuppression monotherapy in kidney transplantation. Selective targeting of post-transplant alloantigen-(re)activated effector-T cells by anti-TNF antibodies after global T cell depletion may allow safe drug minimization, however, it is unsolved what might be the best maintenance monotherapy.Methods
In this open, prospective observational single-centre trial, 20 primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (d0/d1) followed by 5 mg/kg Infliximab (d2). For 14 days all patients received only tacrolimus, then they were allocated to either receive tacrolimus (TAC, n = 13) or sirolimus (SIR, n = 7) monotherapy, respectively. Protocol biopsies and extensive immune monitoring were perfo"],"journal":["PloS one"],"pagination":["e0169624"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5234822"],"repository":["biostudies-literature"],"pubmed_title":["Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial."],"pmcid":["PMC5234822"],"pubmed_authors":["Gerstmayer B","Volk HD","Reinke P","Viklicky O","Schmitz S","Honsova E","Tycova I","Tomiuk S","Sawitzki B","Mrazova P","Miqueu P","Hruba P","Janssen U","Svobodova E"],"additional_accession":[]},"is_claimable":false,"name":"Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial.","description":"Background
There is high medical need for safe long-term immunosuppression monotherapy in kidney transplantation. Selective targeting of post-transplant alloantigen-(re)activated effector-T cells by anti-TNF antibodies after global T cell depletion may allow safe drug minimization, however, it is unsolved what might be the best maintenance monotherapy.Methods
In this open, prospective observational single-centre trial, 20 primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (d0/d1) followed by 5 mg/kg Infliximab (d2). For 14 days all patients received only tacrolimus, then they were allocated to either receive tacrolimus (TAC, n = 13) or sirolimus (SIR, n = 7) monotherapy, respectively. Protocol biopsies and extensive immune monitoring were perfo","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017","modification":"2026-05-03T23:49:42.052Z","creation":"2019-03-26T22:52:47Z"},"accession":"S-EPMC5234822","cross_references":{"pubmed":["28085915"],"doi":["10.1371/journal.pone.0169624"]}}